Caffeine can decrease insulin sensitivity in humans
Keijzers GB, De Galan BE, Tack CJ, Smits P
Diabetes care · 218 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- European Commission
Según 1 financiador declarado.
Publicación
- Publicado
- 2002-02-01 · Diabetes Care · vol. 25 · número 2 · págs. 364–369
- Editorial
- American Diabetes Association
- Citado
- 358 citas · más que el 99% de estudios similares · 9.7× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 42 trabajos
- Acceso
- De pago
- Áreas de investigación
- Coffee research and impacts · Diet, Metabolism, and Disease · Metabolism, Diabetes, and Cancer
- Palabras clave
- caffeine, insulin sensitivity, insulin resistance, catecholamines, epinephrine, norepinephrine, adenosine receptor antagonism, dipyridamole, free fatty acids, glucose uptake, hyperinsulinemic-euglycemic clamp, blood pressure
- MeSH
- humans, hyperinsulinism, insulin resistance, epinephrine, norepinephrine, dipyridamole, caffeine, insulin, central nervous system stimulants, phosphodiesterase inhibitors, glucose clamp technique, double-blind method, adult, female, male
4 autores
- Gerben Keijzers
- Bastiaan E. de Galan
- Cees J. Tack
- Paul Smits
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objective
Caffeine is a central stimulant that increases the release of catecholamines. As a component of popular beverages, caffeine is widely used around the world. Its pharmacological effects are predominantly due to adenosine receptor antagonism and include release of catecholamines. We hypothesized that caffeine reduces insulin sensitivity, either due to catecholamines and/or as a result of blocking adenosine-mediated stimulation of peripheral glucose uptake.
Research design and methods
Hyperinsulinemic-euglycemic glucose clamps were used to assess insulin sensitivity. Caffeine or placebo was administered intravenously to 12 healthy volunteers in a randomized, double-blind, crossover design. Measurements included plasma levels of insulin, catecholamines, free fatty acids (FFAs), and hemodynamic parameters. Insulin sensitivity was calculated as whole-body glucose uptake corrected for the insulin concentration. In a second study, the adenosine reuptake inhibitor dipyridamole was tested using an identical protocol in 10 healthy subjects.
Results
Caffeine decreased insulin sensitivity by 15% (P < 0.05 vs. placebo). After caffeine administration, plasma FFAs increased (P < 0.05) and remained higher than during placebo. Plasma epinephrine increased fivefold (P < 0.0005), and smaller increases were recorded in plasma norepinephrine (P < 0.02) and blood pressure (P < 0.001). Dipyridamole did not alter insulin sensitivity and only increased plasma norepinephrine (P < 0.01).
Conclusions
Caffeine can decrease insulin sensitivity in healthy humans, possibly as a result of elevated plasma epinephrine levels. Because dipyridamole did not affect glucose uptake, peripheral adenosine receptor antagonism does not appear to contribute to this effect.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.